ScholarMate
客服热线:400-1616-289

Clinical expert consensus on the assessment and protection of pancreatic islet ll-cell function in type 2 diabetes mellitus

Zhu, Jian; Han, Junfeng; Liu, Liehua; Liu, Yu; Xu, Wen; Li, Xiaomu; Yang, Lin; Gu, Yong; Tang, Wei; Shi, Yongquan; Ye, Shandong; Hua, Fei; Xiang, Guangda; Liu, Ming; Sun, Zilin; Su, Qing; Li, Xiaoying; Li, Yuxiu; Li, Yanbing; Li, Hong; Li, Yiming; Yang, Tao; Yang, Jing; Shi, Lixin; Yu, Xuefeng; Chen, Li; Shao, Jiaqing; Liang, Jun; Han, Xiao; Xue, Yaomin; Ma, Jianhua*; Zhu, Dalong*; Mu, Yiming*
Science Citation Index Expanded
复旦大学; 华中科技大学; 南方医科大学; 南京大学; 山东大学; 上海交通大学; 中山大学; 中国医学科学院北京协和医院; 1

摘要

Islet ll-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appro-priate assessment of islet ll-cell function is beneficial to better management of T2DM. Protecting islet ll-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet ll-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the "Clinical expert consensus on the assessment and protection of pancreatic islet fl-cell function in type 2 diabetes mellitus." This consensus suggests that 8 -cell function can be clinically assessed using blood glucose -based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet 8 -cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet 8 -cell function, independent of glycemic control.

关键词

Islets ll-cell Functional assessment Weight loss Intensive insulin therapy Expert consensus